http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Taguchi, Satoru,Fukuhara, Hiroshi,Kakutani, Shigenori,Takeshima, Yuta,Miyazaki, Hideyo,Suzuki, Motofumi,Fujimura, Tetsuya,Nakagawa, Tohru,Igawa, Yasuhiko,Kume, Haruki,Homma, Yukio Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.24
Background: Adjuvant androgen deprivation therapy (ADT) is a treatment option for prostate cancer (PC) patients after radical prostatectomy (RP). Although it can achieve a good progression-free survival rate, some patients still develop clinical metastasis. We here investigated risk factors of clinical metastasis in post-prostatectomy patients who received immediate adjuvant ADT. Materials and Methods: We identified 197 patients with non-metastatic PC who underwent RP at our institution between 2000 and 2012, followed by adjuvant ADT. The associations of various clinicopathologic factors with clinical metastasis (primary endpoint) and cancer-specific survival (secondary endpoint) were assessed. Multivariate analysis was conducted using a Cox proportional hazards model. Median follow-up was 87 months after RP. Results: Nine (4.6%) patients developed clinical metastasis and six (3.0%) died from PC. Eight of nine metastatic patients had a pathologic Gleason score (GS) 9 and developed bone metastasis, while the remaining one had pathologic GS 7 and developed metastasis only to para-aortic lymph nodes. On multivariate analyses, pathologic GS ${\geq}9$ and regional lymph node metastasis (pN1) were independent predictors of clinical metastasis and pathologic GS ${\geq}9$ was an independent predictor of cancer-specific death. Conclusions: Pathologic GS ${\geq}9$ and pN1 were independent predictors of clinical metastasis in post-prostatectomy patients who received immediate adjuvant ADT. Furthermore, pathologic GS ${\geq}9$ was an indispensable condition for bone metastasis, which may imply that patients with GS ${\leq}8$ on adjuvant ADT are unlikely to develop bone metastasis.
Predictors of Poor Outcome in Patients with Acute Cerebral Infarction
Nobuhiro Dougu,Shutaro Takashima,Etsuko Sasahara,Yoshiharu Taguchi,Shigeo Toyoda,Tadakazu Hirai,Takashi Nozawa,Kortaro Tanaka,Hiroshi Inoue 대한신경과학회 2011 Journal of Clinical Neurology Vol.7 No.4
Background and Purpose Plasma D-dimer levels are elevated during the acute phase of cerebral infarction (CI). We investigated whether the D-dimer level on admission and other clinical characteristics could be used to predict the poor outcome of patients with acute CI. Methods The clinical characteristics and plasma D-dimer levels measured within 3 days of onset were compared according to outcome among patients with acute CI. Results In total, 359 consecutive patients (mean age, 71.8 years) were examined, of which 174 had a poor outcome [score on the modified Rankin scale (mRS) ≥3] at 30 days after hospitalization. The mean mRS score was higher and a poor outcome was observed more frequently among women than among men (p<0.001 for each). The proportions of women, cardioembolism, atrial fibrillation, advanced age (≥75 years), prior history of CI or transient ischemic attack, and elevated D-dimer level (≥1.0 μg/mL) were significantly higher among patients with a poor outcome than among those with a good outcome. A multivariate analysis showed that elevated D-dimer level [≥1.0 μg/mL; odds ratio (OR), 2.45; 95% confidence interval (95% CI),1.52-3.89; p<0.01], advanced age (OR, 1.93; 95% CI, 1.21-3.07; p<0.01), and female gender (OR, 1.75; 95% CI, 1.08-2.83; p=0.02) were independent predictors of a poor outcome. Conclusions Certain clinical characteristics (gender and advanced age) and an elevated Ddimer level upon admission can be used to predict the outcome of patients with acute CI at 30 days after hospitalization.
Bong Su Kang,Sunghak Choi,Shogo Taguchi,Keishi Suga,Hiroshi Umakoshi,Keesung Kim,Moon Kyu Kwak,Hosup Jung 한국정밀공학회 2024 International Journal of Precision Engineering and Vol.11 No.2
Although a microfluidic technique for vesicle synthesis has drawn attention in the biomedical field due to its superiority in size control and monodispersity, it has suffered from the extraction of residual solvent. Previous studies attempted the solvent-free microfluidic method using the bicelle-to-vesicle transition, but only a limited size of vesicles was obtained with low membrane properties on account of inefficient mixing. In this paper, we suggest the solvent-free and non-stimulus method for the vesicle preparation using a microfluidic chip with different types of mixing structures, among which the tilted-type structure performed an efficient mixing. With this micromixer, lipid vesicles can be continuously obtained at high yields by diluting bicelle solutions composed of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DHPC (1,2-dihexanoyl-sn-glycero-3-phosphocholine). After passing through the microfluidic chip, DMPC bilayer domain coalesced and formed vesicle, while DHPC could dissolve into an aqueous phase. The membrane properties of the vesicles exhibited a highly ordered phase, indicating that DHPCs were removed from transitioned vesicles after dilution in a microfluidic chip. Moreover, by controlling the dilution ratio, vesicles of various sizes ranging from 90 to 480 nm with an enhanced monodispersity can be obtained without any additional process.
박희철,Shinichi Shimizu,Akio Yonesaka,Kazuhiko Tsuchiya,Yasuhiko Ebina,Hiroshi Taguchi,Norio Katoh,Rumiko Kinoshita,Masayori Ishikawa,Noriaki Sakuragi,Hiroki Shirato 연세대학교의과대학 2010 Yonsei medical journal Vol.51 No.1
Purpose: The purpose of this study is to evaluate the clinical results of treatment with a high dose of 3-dimensional conformal boost (3DCB) using a real-time tracking radiation therapy (RTRT) system in cervical cancer patients. Materials and Methods: Between January 2001 and December 2004, 10 patients with cervical cancer were treated with a high dose 3DCB using RTRT system. Nine patients received whole pelvis radiation therapy (RT) with a median dose of 50 Gy (range, 40-50 Gy) before the 3DCB. The median dose of the 3DCB was 30 Gy (range, 25-30 Gy). Eight patients received the 3DCB twice a week with a daily fraction of 5 Gy. The determined endpoints were tumor response, overall survival, local failure free survival, and distant metastasis free survival. The duration of survival was calculated from the time of the start of radiotherapy. Results: All patients were alive at the time of analysis and the median follow-up was 17.6 months (range, 4.9-27.3 months). Complete response was achieved in nine patients and one patient had a partial response. The 1- and 2-year local failure free survival was 78.8% and 54%, respectively. The 1- and 2-year distant metastasis free survival was 90% and 72%, respectively. Late toxicity of a grade 2 rectal hemorrhage was seen in one patient. A subcutaneous abscess was encountered in one patient. Conclusion: The use of the high dose 3DCB in the treatment of cervical cancer is safe and feasible where intracavitary brachytherapy (ICBT)is unable to be performed. The escalation of the 3DCB dose is currently under evaluation.